Clinical trials: Intravascular Ultrasound
- Condition Intravascular Ultrasound
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Atherosclerosis
Integrated Biomarker And Imaging Study - 2
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.
- Trial name
- NCT00268996
- Testing
- SB-480848
- Where
- 26 sites in Austria, Belgium and 9 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Atherosclerosis
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
- Trial name
- NCT00116831
- Testing
- Glipizide, rosiglitazone maleate
- Where
- 156 sites in United States, Argentina and 18 more
- Volunteers
- 672 people
- Sponsor
- GlaxoSmithKline
Peripheral Artery Disease
Evaluation of Imaging of Peripheral Arteries by Optical Coherence Tomography and Intravascular Ultrasound Imaging
A non inferiority trial to determine the capability of optical coherence tomography (OCT) imaging to show vessel morphology in comparison to imaging provided by intravascular ultrasound imaging (IVUS).
- Trial name
- SCAN (NCT03480685)
- Testing
- IVUS and OCT Imaging
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Avinger, Inc.
Coronary Artery Disease
OPTIMIZE PCI: Multicenter Randomized Trial of OCT Compared to IVUS and Angiography to Guide Coronary Stent Implantation
The objective of this clinical investigation is to demonstrate the safety and efficacy of an OCT guided strategy for stent implantation
- Trial name
- ILUMIEN III (NCT02471586)
- Testing
- Coronary PCI guided by IVUS, Coronary PCI guided by OCT, Coronary PCI guided by Angiography
- Where
- 29 sites in United States, Belgium and 6 more
- Volunteers
- 450 people
- Sponsor
- Abbott Medical Devices
Coronary Atherosclerosis
CRESTOR Athero Imaging Head to Head IVUS Study
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular…
- Trial name
- SATURN (NCT00620542)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 195 sites in United States, Argentina and 12 more
- Volunteers
- 2,333 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
This study will be a proof-of-concept, placebo-controlled, double-blind, randomized trial in participants with a recent acute coronary syndrome (ACS) to evaluate the efficacy, pharmacokinetics, safety, tolerability, disease…
- Trial name
- PILOT (NCT02678923)
- Testing
- MDCO-216
- Where
- 20 sites in Canada, Czechia and 3 more
- Volunteers
- 126 people
- Sponsor
- The Medicines Company
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Hypercholesterolemia, Acute Coronary Syndrome
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
Primary Objective: To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in…
- Trial name
- ODYSSEY J-IVUS (NCT02984982)
- Testing
- Alirocumab SAR236553, Atorvastatin, Rosuvastatin
- Where
- 39 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Sanofi
Coronary Artery Disease, Atherosclerosis
The Lipid-Rich Plaque Study
The purpose of this study is to enhance medical knowledge of the causes of future coronary problems. Many studies in patients who have already experienced a coronary problem point to the danger associated with plaques that are…
- Trial name
- LRP (NCT02033694)
- Testing
- NIRS-IVUS Imaging (TVC Imaging System)
- Where
- 41 sites in United States, Italy and 4 more
- Volunteers
- 1,563 people
- Sponsor
- Infraredx
Heart Diseases, Cardiovascular Diseases
Trial Evaluating New Strategy in the Functional Assessment of 3-vessel Disease Using SYNTAXII Score in Patients With PCI
Clinical study that aims to evaluate a new strategy using the SYNTAX II Score calculator in the functional assessment of patients with new coronary 3-vessel-disease who undergo percutaneous coronary intervention (PCI)
- Conditions
- Heart Diseases, Cardiovascular Diseases, 3 Vessel Coronary Artery Disease
- Trial name
- NCT02015832
- Testing
- Coronary stent, Multi Slice Computed Tomography, instantaneous wave-free ratio
- Where
- 22 sites in Netherlands, Poland and 2 more
- Volunteers
- 454 people
- Sponsor
- ECRI bv
Peripheral Artery Disease, PAD
Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
IVUS imaging will be utilized to assess performance of the Sponsor's Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA) in patients who have symptomatic peripheral artery disease (PAD) occurring in…
- Conditions
- Peripheral Artery Disease, PAD, Claudication, Peripheral Vascular Disease
- Trial name
- TRUTH (NCT01938391)
- Testing
- Stealth 360°® OAS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery…
- Trial name
- AQUARIUS (NCT00853827)
- Testing
- Aliskiren
- Where
- 129 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease (CAD)
Imaging of Coronary Plaques in Participants Treated With Evolocumab
To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.
- Trial name
- NCT03570697
- Testing
- Evolocumab, Statin therapy
- Where
- 33 sites in United States, Australia and 5 more
- Volunteers
- 164 people
- Sponsor
- Amgen
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease
Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
The PATHFINDER Registry is a prospective, non-randomized, single arm, multicenter observational study. This pilot registry is aimed to evaluate the performance (peri-procedural) and clinical outcomes (intermediate and long-term)…
- Conditions
- Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
- Trial name
- PATHFINDER (NCT04229563)
- Testing
- AURYON Atherectomy System
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Angiodynamics, Inc.
Peripheral Artery Disease, Critical Limb Ischemia
Complete Lesion Assessment With ffR and IVUS TechnologY
CLARITY I is a pilot study to identify the clinically appropriate endpoint(s) of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia (CLI).
- Trial name
- CLARITY I (NCT01941030)
- Testing
- Orbital Atherectomy System, Balloon Angioplasty
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Disease
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker profile and long-term safety profile of…
- Trial name
- NCT01059682
- Testing
- Dalcetrapib
- Where
- 110 sites in United States, Canada and 3 more
- Volunteers
- 936 people
- Sponsor
- Hoffmann-La Roche
Hypercholesteremia
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography…
- Trial name
- NCT00329160
- Testing
- Rosuvastatin, HMG CoA inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Venous Ulcer of Leg
Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)
This clinical study is a global, prospective, multi-center, randomized controlled trial to determine if the use of intravascular ultrasound (IVUS) as an adjunctive imaging modality and as an interventional treatment guide will…
- Trial name
- IGuideU (NCT04696354)
- Testing
- IVUS, Continued Compression Therapy/Stockings
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 12 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pulmonary Embolism, Deep Vein Thrombosis
Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System
The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF.
- Trial name
- NCT02394912
- Testing
- vena cava filter implantation (LUMIFI with Crux VCF System)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Volcano Corporation
Hypercholesterolemia
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery…
- Trial name
- GLAGOV (NCT01813422)
- Testing
- Evolocumab
- Where
- 226 sites in United States, Argentina and 30 more
- Volunteers
- 970 people
- Sponsor
- Amgen